Literature DB >> 9808190

HLA-A*0201 presents TAP-dependent peptide epitopes to cytotoxic T lymphocytes in the absence of tapasin.

J W Lewis1, A Sewell, D Price, T Elliott.   

Abstract

Tapasin is a 48-kDa endoplasmic reticulum (ER)-resident glycoprotein that binds to the transporter associated with antigen processing (TAP) and mediates an interaction between TAP and newly synthesized MHC class I molecules. It is also essential for the proper antigen presenting function of HLA-A*0101 (HLA-A1), HLA-A*0801 (HLA-B8) and HLA-B*4402 (HLA-B4402). We show here that while tapasin is required for HLA-A*0201 (HLA-A2) molecules to bind to TAP, its absence does not block the presentation of HLA-A2-restricted TAP-dependent epitopes to cytotoxic T lymphocytes indicating that, unlike HLA-A1, HLA-B8 and HLA-B4402, HLA-A2 has access to the TAP-dependent peptide pool even in the absence of tapasin. Nevertheless, the overall efficiency with which HLA-A2 was loaded with optimal, stabilizing peptides was impaired in the cell line .220, resulting in a significant increase in the fraction of HLA-A2 molecules being released from the ER in a "peptide-receptive" state.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9808190     DOI: 10.1002/(SICI)1521-4141(199810)28:10<3214::AID-IMMU3214>3.0.CO;2-C

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  13 in total

Review 1.  The convergent roles of tapasin and HLA-DM in antigen presentation.

Authors:  Scheherazade Sadegh-Nasseri; Mingnan Chen; Kedar Narayan; Marlene Bouvier
Journal:  Trends Immunol       Date:  2008-02-07       Impact factor: 16.687

2.  Cloning and functional analyses of the mouse tapasin promoter.

Authors:  Felix Herrmann; John Trowsdale; Christoph Huber; Barbara Seliger
Journal:  Immunogenetics       Date:  2003-08-26       Impact factor: 2.846

3.  Interaction of TAPBPR, a tapasin homolog, with MHC-I molecules promotes peptide editing.

Authors:  Giora I Morozov; Huaying Zhao; Michael G Mage; Lisa F Boyd; Jiansheng Jiang; Michael A Dolan; Ramesh Venna; Michael A Norcross; Curtis P McMurtrey; William Hildebrand; Peter Schuck; Kannan Natarajan; David H Margulies
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-11       Impact factor: 11.205

4.  Splice acceptor site mutation of the transporter associated with antigen processing-1 gene in human bare lymphocyte syndrome.

Authors:  H Furukawa; S Murata; T Yabe; N Shimbara; N Keicho; K Kashiwase; K Watanabe; Y Ishikawa; T Akaza; K Tadokoro; S Tohma; T Inoue; K Tokunaga; K Yamamoto; K Tanaka; T Juji
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

Review 5.  Spotlight on TAP and its vital role in antigen presentation and cross-presentation.

Authors:  Ian Mantel; Barzan A Sadiq; J Magarian Blander
Journal:  Mol Immunol       Date:  2021-12-29       Impact factor: 4.174

6.  Tapasin enhances MHC class I peptide presentation according to peptide half-life.

Authors:  Mark Howarth; Anthony Williams; Anne B Tolstrup; Tim Elliott
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-30       Impact factor: 11.205

7.  Tapasin-related protein TAPBPR is an additional component of the MHC class I presentation pathway.

Authors:  Louise H Boyle; Clemens Hermann; Jessica M Boname; Keith M Porter; Peysh A Patel; Marian L Burr; Lidia M Duncan; Michael E Harbour; David A Rhodes; Karsten Skjødt; Paul J Lehner; John Trowsdale
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-11       Impact factor: 11.205

8.  The binding of TAPBPR and Tapasin to MHC class I is mutually exclusive.

Authors:  Clemens Hermann; Lisa M Strittmatter; Janet E Deane; Louise H Boyle
Journal:  J Immunol       Date:  2013-10-25       Impact factor: 5.422

Review 9.  The role of tapasin in MHC class I antigen assembly.

Authors:  M J Androlewicz
Journal:  Immunol Res       Date:  1999       Impact factor: 4.505

10.  TAPBPR alters MHC class I peptide presentation by functioning as a peptide exchange catalyst.

Authors:  Clemens Hermann; Andy van Hateren; Nico Trautwein; Andreas Neerincx; Patrick J Duriez; Stefan Stevanović; John Trowsdale; Janet E Deane; Tim Elliott; Louise H Boyle
Journal:  Elife       Date:  2015-10-06       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.